^
BIOMARKER:

ATRX deletion

i
Other names: ATRX, ATRX Chromatin Remodeler, Transcriptional Regulator ATRX, ATP-Dependent Helicase ATRX, X-Linked Nuclear Protein, X-Linked Helicase II, XH2, XNP, Alpha Thalassemia/Mental Retardation Syndrome X-Linked (RAD54 (S. Cerevisiae) Homolog), Alpha Thalassemia/Mental Retardation Syndrome X-Linked (RAD54 Homolog S. Cerevisiae), Alpha Thalassemia/Mental Retardation Syndrome X-Linked, Mental Retardation X-Linked 52, RAD54 Homolog (S. Cerevisiae), Juberg-Marsidi Syndrome, ZNF-HX, Znf-HX, MRX52, JMS
Entrez ID:
Related biomarkers:
2ms
The mutational spectrum of ATRX aberrations in neuroblastoma and the associated patient and tumor characteristics. (PubMed, Cancer Sci)
Surprisingly, we found that 11q deletions are enriched in neuroblastomas with ATRX deletions compared to a reference cohort, but not in neuroblastomas with ATRX point mutations. Taken together our data emphasizes a distinct ATRX mutation spectrum in neuroblastoma, which should be considered when studying molecular phenotypes and therapeutic strategies.
Journal
|
ATRX (ATRX Chromatin Remodeler)
|
Chr del(11q) • ATRX mutation • ATRX deletion
9ms
ATRX DELETION IMPAIRS CGAS-STING SIGNALING AND INCREASES RESPONSE TO RADIATION AND ONCOLYTIC HERPESVIRUS IN SOFT TISSUE SARCOMA (CTOS 2021)
To generate the first primary mouse model of soft tissue sarcoma, 4-hydroxytamoxifen (4-OHT) was injected into the gastrocnemius muscle... Collectively, these results show that loss of ATRX function impairs the cGAS-STING signaling pathway in soft tissue sarcomas and promotes their response to radiation therapy and oncolytic virus therapy. These findings identify ATRX as a biomarker in treatment response and identify novel genomically-informed therapeutic strategies for treatment of soft tissue sarcoma.
Oncolytic virus • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • ATRX (ATRX Chromatin Remodeler)
|
KRAS G12D • KRAS G12 • TP53 expression • ATRX deletion • KRAS deletion • KRAS expression
|
tamoxifen
9ms
Feasibility of Single-Pass Stereotactic Needle Biopsy in Recurrent Glioblastoma Patients to Support CLIA-Certified Tumor Pharmacodynamics for a Phase 0/2 Clinical Trial (SNO 2021)
Based on IHC and genetic analyses of the biopsied samples, three patients were enrolled into the Phase 0/2 clinical trial and baseline value were used for PD analysis. CONCLUSION Single-pass stereotactic needle biopsy is a feasible and safe strategy to collect pre-treatment tissue in support of a Phase 0 clinical trial, enabling CLIA-certified genetic analysis for trial screening and tumor PD analysis.
Clinical • PK/PD data
|
TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • ATRX (ATRX Chromatin Remodeler)
|
TP53 mutation • PTEN mutation • CDKN2A deletion • ATRX mutation • ATRX deletion
1year
Molecular diagnostics helps to identify distinct subgroups of spinal astrocytomas. (PubMed, Acta Neuropathol Commun)
DMG-H3 tend to develop in adolescence with a similar dismal prognosis like GBM and HAP in the elderly. We here describe spinal HAP with a distinct molecular profile for the first time.
Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • ATRX (ATRX Chromatin Remodeler)
|
PIK3CA mutation • CDKN2A deletion • ATRX mutation • ATRX deletion